The expression of TUBB3 is reported to be not only associated with the progression of CRPC in a study enrolling 138 human prostate tumor specimens [39] but is also able to predict the treatment response to taxene-based chemotherapy for CRPC [40]. The gene discussed is TUBB3; the disease is prostate neoplasm.